eMedicine Specialties > Radiology > Brain/Spine

Neurofibromatosis Type 2: Imaging

Author: Andrew L Wagner, MD, Assistant Professor of Radiology, Instructional Faculty, University of Virginia School of Medicine; Director of Neuroradiology, Department of Radiology, Rockingham Memorial Hospital
Contributor Information and Disclosures

Updated: Mar 17, 2008

Radiography

Findings

Intracranial abnormalities found in NF2 are not visible on plain radiographs, except in cases of hyperostosis from a meningioma. Widening of the neural foramina and scalloping of the posterior aspect of the vertebral bodies can be seen on plain radiographs of the spine and result from pressure erosion from the schwannomas rather than the dural ectasia that causes the bony malformations in NF1. Scoliosis is also associated with NF2 and can be measured most accurately on plain radiographs, although CT scan studies or MRI may be necessary to evaluate some of the more subtle spinal deformities.

Degree of Confidence

Foraminal widening and posterior vertebral scalloping is not specific for NF2. The dural ectasia of NF1, as well as some bone dysplasias, can cause scalloping of the posterior vertebral bodies similar to that seen in NF2; however, the scalloping in NF2 is a result of associated tumors. Although the scalloping from NF1 and NF2 are occasionally indistinguishable on plain radiographs, either MRI or CT scanning easily distinguishes between the 2.

NF2 is associated with scoliosis, but it is an uncommon cause of scoliosis, and no study has described scoliosis as a presenting sign of NF2.

Computed Tomography

Findings

  • CN VIII schwannomas are visualized on CT scans as strongly, but heterogeneously, enhancing cerebellopontine angle masses that extend from the IAC. On precontrast imaging, these schwannomas are isodense to hypodense with respect to brain tissue and may have associated cysts or hemorrhage. The pressure of the tumor often results in widening of the IAC and is best visualized using bone windows. Gas CT cisternography, with 0.5- to 1-mm slices, can demonstrate small tumors within the IAC that are typically missed on routine CT scanning. Small schwannomas of the other CNs are easily overlooked or not visualized because of their proximity to osseous structures and the relatively poor contrast resolution of CT scanning.
  • Intracranial meningiomas present as enhancing extra-axial masses, often with internal calcifications and adjacent hyperostosis that are best visualized with bone windows. Adjacent white matter with decreased attenuation is commonly seen when tumors are large, likely representing edema. The persistence of this abnormality for years after the tumor has been resected suggests the likely existence of a demyelinating factor as well. When large enough, meningiomas may exhibit mass effect on the brain parenchyma and can be aggressive at times, invading the adjacent bone. Without contrast, meningiomas may have the same attenuation as the brain, but they typically have higher attenuation values resulting from the presence of calcium and a high nuclear-to-cytoplasmic ratio. Small tumors can be missed, particularly over the calvarium and in the posterior fossa, where beam-hardening artifact is the worst.
  • Spinal schwannomas appear either as dumbbell-shaped enhancing masses extending out the neural foramina or as intradural extramedullary masses in the spinal canal. CT scans show widening of the foramina or pressure erosion on the adjacent vertebral body, and sagittal reformatted images are useful.
  • Spinal meningiomas are found as intradural extramedullary masses, usually in the thoracic spine. They are best imaged on CT myelography, although they usually show enhancement on contrast CT scans. Occasionally, meningiomas extend into the neural foramina and appear as dumbbell-shaped masses with widening of the neural foramina. In these cases, distinguishing them from schwannomas or neurofibromas is difficult.
  • Spinal ependymomas are intra-axial enhancing masses seen most frequently in the cervical cord and conus. When involving the conus or filum, an ependymoma may be pedunculated and appear as an extra-axial mass. Cervical cord ependymomas are well-marginated enhancing tumors that may exhibit associated cyst formation.

Degree of Confidence

Perform CT scanning only in patients with NF2 in whom MRI is contraindicated, because MRI provides superior tumor imaging and characterization. When CT scanning must be used, perform high-resolution techniques in the axial and coronal planes and consider CT cisternography for detecting small tumors. Even when visualized, the type of tumor is often difficult to identify on CT scans, because a large amount of overlap is seen in tumor appearance. CT myelography is adequate in depicting the extra-axial lesions of NF2, but it is relatively poor at detecting ependymomas. CT scanning with 3-dimensional (3-D) volumetric rendering can be useful for preoperative planning in patients with NF2 and associated scoliosis or spinal dystrophy.

Magnetic Resonance Imaging

Findings

CN VIII schwannomas are well-defined masses arising from the IAC and frequently extend into the cerebellopontine angle, demonstrating an ice cream cone or mushroom shape (see Image 1).

  • CN VIII schwannomas often have heterogeneous signals, but they are typically isointense to hypointense on T1-weighted images and hyperintense on T2-weighted images.
  • High-resolution, heavily T2-weighted sequences have been used to detect small CN VIII schwannomas and appear to be approximately as sensitive as contrast MRI.
  • Using this technique, the bright cerebrospinal fluid (CSF) around CN VII and CN VIII is used as a contrast agent, and schwannomas appear as small rounded masses that efface the CSF in the canal.
  • This technique is also useful in detecting cochlear involvement by the tumor, because the cochlear turns can normally be easily identified as curvilinear areas of increased signal.

Following contrast administration, CN VIII schwannomas enhance avidly but often heterogeneously, particularly in larger tumors.

Nonenhancing areas of necrosis are often present as the schwannomas enlarge, and associated cysts or blood products from internal hemorrhage may be present.

Other CN schwannomas have a similar MRI appearance and differ only in location, occurring along the paths of the other CNs. The multiplanar capability of MRI is particularly useful in distinguishing a CN schwannoma from a meningioma adjacent to a nerve.

Meningiomas in NF2 have the same distribution and signal characteristics as spontaneous meningiomas, occurring most frequently along the falx and over the convexities (see Image 2).

  • Meningiomas are extra-axial tumors and thus demonstrate cortical buckling and a CSF cleft.
  • A confluent area of white matter with increased T1 signal and decreased T2 signal may be seen in the adjacent brain parenchyma and likely results from a combination of vasogenic edema and demyelination.
  • Meningiomas typically are isointense with gray matter on all sequences and, when small, can be difficult to detect without contrast.
  • Signal intensity can vary, and almost any combination of T1 and T2 signals can be seen.
  • Cyst formation is uncommon, but calcification occurs frequently and can cause the tumor to appear heterogeneous.
  • Following gadolinium administration, intense and generally homogeneous enhancement is seen, and a dural tail of enhancing dural tissue is often found extending from the tumor's dural attachment, although this is not specific for meningioma.27,28
  • Meningiomas in patients with NF2 may be more aggressive than spontaneously occurring ones, and the tumor may invade the adjacent calvarium and extend into the paranasal sinuses (see Image 3).

Spinal meningiomas are also associated with NF2 and are often multiple in number. Unlike intracranial meningiomas, the spinal type calcifies in fewer than 10% of patients (see Image 4).

  • Spinal meningiomas are typically intradural and extra-axial but can present as dumbbell-shaped masses extending through the neural foramina. In this situation, distinction from a neurofibroma or schwannoma is difficult, although the schwannoma should be brighter on T2-weighted images.
  • Meningiomas are usually isointense relative to the spinal cord on all image sequences and enhance strongly following gadolinium administration.
  • Although most spinal meningiomas have a broad dural attachment similar to their intracranial counterparts, dural tail signs are found less frequently in spinal meningiomas.

Spinal ependymomas found in NF2 are divided into 2 groups: those that occur in the upper cord and those that occur in the conus.

  • Cord tumors are well-marginated, intensely enhancing lesions, frequently associated with cyst formation and hemorrhage. Ependymomas may be isointense or hypointense relative to the spinal cord on T1-weighted images and are always bright on T2-weighted images, although a peripheral rim of decreased T2 signal has been proposed as being suggestive of ependymoma.
  • Conus ependymomas are more often large tumors that can fill the entire spinal canal with heterogeneous signal and enhancement. When small, the tumors may be well-marginated intra-axial lesions, but when larger, they may appear to arise from the extra-axial space.

Multiple extradural masses extending through the neural foramina are found in both NF1 and NF2, although in NF2 (unlike in NF1), these tumors are usually schwannomas. The tumors often have both an intraspinal and an extraspinal component, demonstrate a classic dumbbell shape, and are typically multilevel and bilateral. Signal intensities for spinal schwannomas are the same as those for intracranial schwannomas, and strong contrast enhancement is seen. Because of the multifocality of the spinal schwannomas and an association with scoliosis, coronal MRI often is helpful.

Gadolinium-based contrast agents (gadopentetate dimeglumine [Magnevist], gadobenate dimeglumine [MultiHance], gadodiamide [Omniscan], gadoversetamide [OptiMARK], gadoteridol [ProHance]) have recently been linked to the development of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD). For more information, see the eMedicine topic Nephrogenic Fibrosing Dermopathy. The disease has occurred in patients with moderate to end-stage renal disease after being given a gadolinium-based contrast agent to enhance MRI or MRA scans.

As of late December 2006, the FDA had received reports of 90 such cases. Worldwide, over 200 cases have been reported, according to the FDA. NSF/NFD is a debilitating and sometimes fatal disease. Characteristics include red or dark patches on the skin; burning, itching, swelling, hardening, and tightening of the skin; yellow spots on the whites of the eyes; joint stiffness with trouble moving or straightening the arms, hands, legs, or feet; pain deep in the hip bones or ribs; and muscle weakness. For more information, see the FDA Public Health Advisory or Medscape.

Degree of Confidence

MRI is the imaging modality of choice in NF2 and is accurate in detecting even small tumors. Separation of intracranial schwannomas from meningiomas may be difficult at times but is usually of little clinical value. The evaluation of the extent, size, and number of intracranial tumors in NF2 is accomplished best by MRI because of its multiplanar capability, its contrast resolution, and the spectrum of pulse sequences, each of which adds different information.

Spinal schwannomas, meningiomas, and ependymomas are also visualized best on MRI. Usually, no other imaging modality is necessary either at the time of diagnosis or as part of a follow-up regimen. Although MRI can image osseous vertebral abnormalities associated with NF2, CT scanning visualizes them better.

Angiography

Findings

Angiography is of limited use in NF2 because most tumors are not visualized. An exception is the "mother-in-law sign" ("arrives early and stays late") of meningioma contrast enhancement. This sign comes from recognition of meningiomas during angiography by their early contrast enhancement and delayed washout. The early contrast enhancement is caused by the enlarged feeding vessels, usually pial or meningeal arteries, and the delayed tumor staining is from lack of capillary blood-brain barriers within the tumor. Unfortunately, like many signs in radiology, this is not specific and can be seen in other hypervascular tumors.

Because ependymomas and schwannomas are not particularly vascular, they are often not visible on angiography; however, when large enough, secondary mass effect on the adjacent brain can be recognized.

More on Neurofibromatosis Type 2

Overview: Neurofibromatosis Type 2
Imaging: Neurofibromatosis Type 2
Follow-up: Neurofibromatosis Type 2
Multimedia: Neurofibromatosis Type 2
References

References

  1. Baser ME, R Evans DG, Gutmann DH. Neurofibromatosis 2. Curr Opin Neurol. Feb 2003;16(1):27-33. [Medline].

  2. Bance M, Ramsden RT. Management of neurofibromatosis type 2. Ear Nose Throat J. Feb 1999;78(2):91-4, 96. [Medline].

  3. Evans DG. Neurofibromatosis type 2: genetic and clinical features. Ear Nose Throat J. Feb 1999;78(2):97-100. [Medline].

  4. Jacoby LB, MacCollin M, Parry DM, et al. Allelic expression of the NF2 gene in neurofibromatosis 2 and schwannomatosis. Neurogenetics. Apr 1999;2(2):101-8. [Medline].

  5. Fontaine B, Sanson M, Delattre O, et al. Parental origin of chromosome 22 loss in sporadic and NF2 neuromas. Genomics. May 1991;10(1):280-3. [Medline].

  6. Fontaine B, Hanson MP, VonSattel JP, et al. Loss of chromosome 22 alleles in human sporadic spinal schwannomas. Ann Neurol. Feb 1991;29(2):183-6. [Medline].

  7. National Institutes of Health. Consensus Development Conference. Neurofibromatosis Conference Statement. Arch Neurol. 1988;45 (5):575-8. [Medline].

  8. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. Jul 2 1997;278(1):51-7. [Medline].

  9. Bosch MM, Boltshauser E, Harpes P, Landau K. Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2. Am J Ophthalmol. Jun 2006;141(6):1068-77. [Medline].

  10. Landau K, Yasargil GM. Ocular fundus in neurofibromatosis type 2. Br J Ophthalmol. Oct 1993;77(10):646-9. [Medline].

  11. Kaye LD, Rothner AD, Beauchamp GR, et al. Ocular findings associated with neurofibromatosis type II. Ophthalmology. Sep 1992;99(9):1424-9. [Medline].

  12. Landau K, Dossetor FM, Hoyt WF, Muci-Mendoza R. Retinal hamartoma in neurofibromatosis 2. Arch Ophthalmol. Mar 1990;108(3):328-9. [Medline].

  13. Smirniotopoulos JG, Murphy FM. The phakomatoses. AJNR Am J Neuroradiol. Mar-Apr 1992;13(2):725-46. [Medline].

  14. Antinheimo J, Sankila R, Carpen O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. Jan 11 2000;54(1):71-6. [Medline].

  15. Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. Dec 1992;29(12):841-6. [Medline].

  16. Baser ME, Evans DG, Jackler RK, et al. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer. Feb 2000;82(4):998. [Medline].

  17. Baser ME, Friedman JM, Aeschliman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. Oct 2002;71(4):715-23. [Medline][Full Text].

  18. Evans DG, Baser ME, O'Reilly B, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg. Feb 2005;19(1):5-12. [Medline].

  19. Baser ME, Evans DG. Lack of sex-ratio distortion in neurofibromatosis 2. Am J Med Genet. Nov 27 2000;95(3):292. [Medline].

  20. MacCollin M, Mautner VF. The diagnosis and management of neurofibromatosis 2 in childhood. Semin Pediatr Neurol. Dec 1998;5(4):243-52. [Medline].

  21. Gillespie JE. Imaging in neurofibromatosis type 2: screening using magnetic resonance imaging. Ear Nose Throat J. Feb 1999;78(2):102-3, 106, 108-9. [Medline].

  22. Mautner VF, Tatagiba M, Lindenau M, et al. Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am J Roentgenol. Oct 1995;165(4):951-5. [Medline][Full Text].

  23. Egelhoff JC, Bates DJ, Ross JS, et al. Spinal MR findings in neurofibromatosis types 1 and 2. AJNR Am J Neuroradiol. Jul-Aug 1992;13(4):1071-7. [Medline].

  24. Beges C, Revel MP, Gaston A, et al. Trigeminal neuromas: assessment of MRI and CT. Neuroradiology. 1992;34(3):179-83. [Medline].

  25. Allen RW, Harnsberger HR, Shelton C, et al. Low-cost high-resolution fast spin-echo MR of acoustic schwannoma: an alternative to enhanced conventional spin-echo MR?. AJNR Am J Neuroradiol. Aug 1996;17(7):1205-10. [Medline].

  26. Kingsley DP, Brooks GB, Leung AW, Johnson MA. Acoustic neuromas: evaluation by magnetic resonance imaging. AJNR Am J Neuroradiol. Jan-Feb 1985;6(1):1-5. [Medline].

  27. Tien RD, Yang PJ, Chu PK. "Dural tail sign": a specific MR sign for meningioma?. J Comput Assist Tomogr. Jan-Feb 1991;15(1):64-6. [Medline].

  28. Goldsher D, Litt AW, Pinto RS, et al. Dural "tail" associated with meningiomas on Gd-DTPA-enhanced MR images: characteristics, differential diagnostic value, and possible implications for treatment. Radiology. Aug 1990;176(2):447-50. [Medline].

  29. Allcutt DA, Hoffman HJ, Isla A, et al. Acoustic schwannomas in children. Neurosurgery. Jul 1991;29(1):14-8. [Medline].

  30. Aoki S, Barkovich AJ, Nishimura K, et al. Neurofibromatosis types 1 and 2: cranial MR findings. Radiology. Aug 1989;172(2):527-34. [Medline].

  31. Arts WF, Van Dongen KJ. Intracranial calcified deposits in neurofibromatosis. J Neurol Neurosurg Psychiatry. Nov 1986;49(11):1317-20. [Medline].

  32. Baldwin D, King TT, Chevretton E, Morrison AW. Bilateral cerebellopontine angle tumors in neurofibromatosis type 2. J Neurosurg. Jun 1991;74(6):910-5. [Medline].

  33. Celli P, Ferrante L, Acqui M, et al. Neurinoma of the third, fourth, and sixth cranial nerves: a survey and report of a new fourth nerve case. Surg Neurol. Sep 1992;38(3):216-24. [Medline].

  34. Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med. Aug 1992;84(304):603-18. [Medline].

  35. Evans DG, Lye R, Neary W, et al. Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma. J Neurol Neurosurg Psychiatry. Jun 1999;66(6):764-7. [Medline].

  36. Evans DG, Ramsden RT, Shenton A, et al. What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumors?. J Neurosurg. Jan 2008;108(1):92-6. [Medline].

  37. Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol. Apr 2007;6(4):340-51. Review. [Medline].

  38. Halliday AL, Sobel RA, Martuza RL. Benign spinal nerve sheath tumors: their occurrence sporadically and in neurofibromatosis types 1 and 2. J Neurosurg. Feb 1991;74(2):248-53. [Medline].

  39. Hope DG, Mulvihill JJ. Malignancy in neurofibromatosis. Adv Neurol. 1981;29:33-56. [Medline].

  40. Kanter WR, Eldridge R. Maternal effect in central neurofibromatosis. Lancet. Oct 21 1978;2(8095):903. [Medline].

  41. Kim HW, Weinstein SL. Spine update. The management of scoliosis in neurofibromatosis. Spine. Dec 1 1997;22(23):2770-6. [Medline].

  42. King A, Gutmann DH. The question of familial meningiomas and schwannomas: NF2B or not to be?. Neurology. Jan 11 2000;54(1):4-5. [Medline].

  43. Kishore A, O'Reilly BF. A clinical study of vestibular schwannomas in type 2 neurofibromatosis. Clin Otolaryngol Allied Sci. Dec 2000;25(6):561-5. [Medline].

  44. Louw D, Sutherland G, Halliday W, Kaufmann J. Meningiomas mimicking cerebral schwannoma. J Neurosurg. Nov 1990;73(5):715-9. [Medline].

  45. Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med. Mar 17 1988;318(11):684-8. [Medline].

  46. Mayfrank L, Mohadjer M, Wullich B. Intracranial calcified deposits in neurofibromatosis type 2. A CT study of 11 cases. Neuroradiology. 1990;32(1):33-7. [Medline].

  47. Mulvihill JJ, Parry DM, Sherman JL, et al. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med. Jul 1 1990;113(1):39-52. [Medline].

  48. Patronas NJ, Courcoutsakis N, Bromley CM, et al. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology. Feb 2001;218(2):434-42. [Medline].

  49. Schefler AC, Dubovy SR, Berrocal AM. Optical coherence tomography characteristics of epiretinal membranes in neurofibromatosis 2. Ophthalmic Surg Lasers Imaging. ;. Jan-Feb 2008;39(1):73-7. [Medline].

  50. Stuckey SL, Harris AJ, Mannolini SM. Detection of acoustic schwannoma: use of constructive interference in the steady state three-dimensional MR. AJNR Am J Neuroradiol. Aug 1996;17(7):1219-25. [Medline].

  51. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. Oct 15 1997;278(15):1262-7. [Medline].

  52. Yamakami I, Oishi H, Iwadate Y, Yamaura A. Isolated metastases of adenocarcinoma in the bilateral internal auditory meatuses mimicking neurofibromatosis type 2--case report. Neurol Med Chir (Tokyo). Oct 1999;39(11):756-61. [Medline].

Further Reading

Keywords

neurofibromatosis with bilateral acoustic neuromas, NF2, neurofibromatosis 2, central neurofibromatosis, NF-2, neurofibromatosis II, schwannomatosis, MISME syndrome

Contributor Information and Disclosures

Author

Andrew L Wagner, MD, Assistant Professor of Radiology, Instructional Faculty, University of Virginia School of Medicine; Director of Neuroradiology, Department of Radiology, Rockingham Memorial Hospital
Andrew L Wagner, MD is a member of the following medical societies: American College of Radiology, American Roentgen Ray Society, American Society of Neuroradiology, and Radiological Society of North America
Disclosure: Nothing to disclose.

Medical Editor

Mahesh R Patel, MD, Chief of MRI, Department of Radiology, Santa Clara Valley Medical Center
Mahesh R Patel, MD is a member of the following medical societies: Radiological Society of North America
Disclosure: Nothing to disclose.

Pharmacy Editor

Bernard D Coombs, MB, ChB, PhD, Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand
Disclosure: Nothing to disclose.

Managing Editor

Robert L DeLaPaz, MD, Director, Professor, Department of Radiology, Division of Neuroradiology, Columbia University
Robert L DeLaPaz, MD is a member of the following medical societies: American Society of Neuroradiology, Association of University Radiologists, and Radiological Society of North America
Disclosure: Nothing to disclose.

CME Editor

Robert M Krasny, MD, Consulting Staff, Department of Radiology, The Angeles Clinic and Research Institute
Robert M Krasny, MD is a member of the following medical societies: American Roentgen Ray Society and Radiological Society of North America
Disclosure: Nothing to disclose.

Chief Editor

James G Smirniotopoulos, MD, Professor of Radiology, Neurology, and Biomedical Informatics, Chairman, Department of Radiology and Radiological Sciences, Uniformed Services University of the Health Sciences
James G Smirniotopoulos, MD is a member of the following medical societies: American College of Radiology, American Roentgen Ray Society, American Society of Head and Neck Radiology, American Society of Neuroradiology, American Society of Pediatric Neuroradiology, Association of University Radiologists, and Radiological Society of North America
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.